Desacyl ghrelin

Phase 1Biologic

IImperial College London

Desacyl ghrelin is one of 45 biologic programs targeting Alcohol Dependence. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcohol DependenceActive, not recruiting

Alcohol DependencePhase 1

Active, not recruiting

Competition

Competitive Landscape

116 competitors in Alcohol Dependence

#DrugCompanyPhaseTrials

Depakote

Zyprexa

2 3

Tums

Otsuka

Phase 3

1 4

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

1 5

Inversine

TTargacept Inc.

Phase 3

1 6

Seroquel

AstraZeneca

Phase 3

1 7

Lioresal

Novartis

Phase 2

4 8

Byetta

AstraZeneca

Phase 2

2 9

Epidiolex

Jazz Pharmaceuticals

Phase 2

2 10

Alcohol

Astellas

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alcohol Dependence1 trial

Gut Hormones in Obesity, Nicotine and Alcohol Dependence

Unknown status·IImperial College London·Phase 1·NCT02690987·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Desacyl ghrelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Desacyl ghrelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Desacyl ghrelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Imperial College London company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: IImperial College London

Desacyl ghrelin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alcohol Dependence1 trial

References

Drug Info

Quick Facts

Related News